HMGB1 and atherosclerosis: To confirm the potential role and underlying mechanism of HMGB1 in CUMS-induced atherosclerosis, CUMS ApoE-/- mice were treated with HMGB1 inhibitor EP and TLR4 inhibitor TAK-242, respectively.